Clinical Trial Update: Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating arsenic trioxide for relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Arsenic Trioxide (Trisenox) (arsenic trioxide)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Status: COMPLETED